A biotech that’s developing a drug for a rare metabolic disorder is exploring going public in 2019
|10/13/2018||Posted by BusinessMediaguide.Com under General World News||
- New York-based biotech Applied Therapeutics is exploring an initial public offering in the first half of 2019, according to people familiar with the matter.
- The company’s developing a drug for a rare metabolic disorder, as well as treatments for diabetes complications.
The red hot market for biotech IPOs may have another entrant.
New York-based Applied Therapeutics, which is developing treatments for cardio-metabolic conditions, is exploring an IPO that could land in first half of next year, according to people familiar with the matter.
The people cautioned that timing could change depending on market conditions.